Annexin Pharmaceuticals AB (publ)

OM:ANNX BTA Stock Report

Market Cap: SEK 156.7m

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Annexin Pharmaceuticals Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of ANNX BTA?
Owner TypeNumber of SharesOwnership Percentage
Private Companies8,153,2142.35%
Institutions16,354,0474.72%
General Public62,801,82718.1%
Individual Insiders259,274,60074.8%

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 114.1%.

Top Shareholders

Top 20 shareholders own 82.25% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
25.9%
Mikael Lonn
89,716,060SEK 40.6m138%no data
18.5%
Arne Andersson
64,041,911SEK 28.9m143%no data
8.47%
Sebastian Jahreskog
29,348,380SEK 13.3m148%no data
7.57%
Magnus Claesson
26,245,066SEK 11.9m144%no data
6.34%
Lars Hallén
21,983,544SEK 9.9m0%no data
2.77%
Nordnet AB (publ), Asset Management Arm
9,613,523SEK 4.3m123%0.05%
2.55%
Thorbjörn Fridh
8,825,000SEK 4.0m0%no data
2.17%
Mattias Willman
7,507,061SEK 3.4m156%no data
1.94%
Avanza Fonder AB
6,740,524SEK 3.0m125%0.01%
1.8%
Lars Hallen
6,240,000SEK 2.8m0%no data
1.67%
Medirista Ab
5,783,918SEK 2.6m1,050%no data
1.26%
Torbjörn Fridh
4,355,000SEK 2.0m0%no data
0.68%
Frostskog Ab
2,369,296SEK 1.1m0%no data
0.28%
Anders Haegerstrand
985,008SEK 445.2k181%no data
0.18%
Carl-Fredrik Lindner
640,005SEK 289.3k357%no data
0.061%
Uli Hacksell
210,000SEK 94.9k110%no data
0.055%
Susan Suchdev
189,560SEK 85.7k175%no data
0.05%
Henrik Palm
175,000SEK 79.1k0%no data
0.014%
Anthon Jahreskog
47,649SEK 21.5k110%no data
0.013%
Gisela Sitbon
44,100SEK 19.9k110%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/06/15 15:39
End of Day Share Price 2024/06/14 00:00
Earnings2024/03/31
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Annexin Pharmaceuticals AB (publ) is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Fredrik ThorRedeye